FBLG vs. DSGN, ENGN, PLX, OCGN, AMRN, NVCT, MDWD, RZLT, CRDF, and IVA
Should you be buying FibroBiologics stock or one of its competitors? The main competitors of FibroBiologics include Design Therapeutics (DSGN), enGene (ENGN), Protalix BioTherapeutics (PLX), Ocugen (OCGN), Amarin (AMRN), Nuvectis Pharma (NVCT), MediWound (MDWD), Rezolute (RZLT), Cardiff Oncology (CRDF), and Inventiva (IVA). These companies are all part of the "pharmaceutical products" industry.
FibroBiologics vs.
FibroBiologics (NASDAQ:FBLG) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.
FibroBiologics received 3 more outperform votes than Design Therapeutics when rated by MarketBeat users. Likewise, 100.00% of users gave FibroBiologics an outperform vote while only 33.33% of users gave Design Therapeutics an outperform vote.
Design Therapeutics is trading at a lower price-to-earnings ratio than FibroBiologics, indicating that it is currently the more affordable of the two stocks.
56.6% of Design Therapeutics shares are held by institutional investors. 20.8% of FibroBiologics shares are held by company insiders. Comparatively, 31.2% of Design Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
FibroBiologics has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500.
FibroBiologics currently has a consensus price target of $13.00, indicating a potential upside of 965.57%. Design Therapeutics has a consensus price target of $8.00, indicating a potential upside of 106.19%. Given FibroBiologics' stronger consensus rating and higher possible upside, equities analysts plainly believe FibroBiologics is more favorable than Design Therapeutics.
FibroBiologics' return on equity of 0.00% beat Design Therapeutics' return on equity.
In the previous week, Design Therapeutics had 3 more articles in the media than FibroBiologics. MarketBeat recorded 4 mentions for Design Therapeutics and 1 mentions for FibroBiologics. Design Therapeutics' average media sentiment score of 0.44 beat FibroBiologics' score of 0.00 indicating that Design Therapeutics is being referred to more favorably in the news media.
Summary
FibroBiologics beats Design Therapeutics on 10 of the 16 factors compared between the two stocks.
Get FibroBiologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FBLG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
FibroBiologics Competitors List
Related Companies and Tools
This page (NASDAQ:FBLG) was last updated on 4/26/2025 by MarketBeat.com Staff
Buy FBLG Stock Free FBLG Stock Alerts